Few studies have included renal dysfunction in their risk stratification scheme for stroke.
We tested the predictive power of the main scoring schemes for risk of stroke advocated in international guidelines against the observed rates of stroke and thromboembolic events in people aged over 75 with chronic atrial fibrillation recruited to the BAFTA trial.
The most commonly used scheme for stratifying risk of stroke is the CHADS2 (Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack (TIA) (double weight)) score which has a range 0 6.
8 9 10 The most commonly used scheme for stratifying the risk of stroke is the CHADS2 (Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, previous Stroke/transient ischaemic attack (doubled risk weight)) score.
Objective To compare the predictive power of the main existing and recently proposed schemes for stratification of risk of stroke in older patients with atrial fibrillation.
Schemes for stratifying the risk of stroke have been largely derived from non-anticoagulated arms of clinical trial cohorts, in which many potential thromboembolic risk factors were not recorded.
We referred to clinical risk stratification schemes [ 1, 5, 21, 22], including one local scheme [ 1], to classify the risk of stroke as "moderate-low" (case 1) and "high" (cases 2 and 3).
Stratification schemes are available to quantify the risk of stroke in patients with AF (Table 7).
To aid in the assessment of stroke risk, several risk stratification schemes or clinical prediction rules have been developed.
Numerous risk stratification schemes have been developed to help predict the level of stroke risk in patients with AF (low, moderate, or high) and to manage them accordingly.
